Why grandparents can’t find vaccines: Scarcity of niche biotech ingredients

February 19, 2021

(Washington Post) Scaling up production of formerly niche substances such as lipid nanoparticles for a global vaccine drive has been among the most complex challenges facing the Biden administration as it aims to ramp up the frustratingly slow provision of shots across the country, according to interviews with company officials and outside scientists and government reports.